Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease.
We evaluated the effectiveness of Re-186-HEDP in 25 patients with painful metastatic bone disease. Twenty-five patients with known prostatic (n = 19), non-small-cell lung cancer (n = 1) and breast cancer (n = 5) and multiple confirmed skeletal metastases were studied. All were taking analgesics daily (nonsteroidal antiinflammatory drugs/opiates). Re-186-HEDP (mean 35.2 mCi) was administered and patients were monitored for at least 50 days. In five patients, a repeat dose was administered 9 to 10 weeks later. The evaluation of the analgesic effect was based on a "pain diary" and by recording the use of analgesics. In 80% (20 of 25) of the patients, the effect was significant palliation, moderate in 3 patients (12%), and insignificant in 2 (8%). No significant myelotoxicity was observed. Transient pain flare was recorded in 8 of 25 patients. These results indicate that Re-186-HEDP can offer pain palliation in patients with painful bone metastases without being complicated by significant myelotoxicity.
Giannakenas
C
C
Department of Nuclear Medicine, University Hospital of Patras, Greece. cgian@med.upatras.gr
Kalofonos
H P
HP
Apostolopoulos
D J
DJ
Zarakovitis
J
J
Kosmas
C
C
Vassilakos
P J
PJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000473:pathology; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010148:Intractable Pain / Q000209:etiology / Q000628:therapy*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000473:pathology; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C064573:rhenium-186(tin)etidronate; D012968:Etidronic Acid